Alector Inc (ALEC) Unusual Options Activity Today

Checking ALEC unusual options activity helps you spot when traders are making outsized bets on Alector Inc before the broader market catches on. Alector Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ALEC unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ALEC unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ALEC unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ALEC unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Catalysts rarely arrive without a footprint, and ALEC unusual options activity is often where that footprint shows up first. Our scanner tracks Alector Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ALEC unusual options volume on the call side or chasing put sweeps, Alector Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.